Employment among patients with kidney disease remains low even after dialysis or a transplant, with physical and social ...

Comparison of eGFR change rates before and after renal internal medical referral. Before the referral (left orange), the ...

But a new study from researchers at the University of Bristol offers fresh hope. It looks at how a well-known medicine called ...

Two significant programs that invested in research on diabetes, dementia, obesity and kidney disease have ended since the ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

(Courtesy/GettyImages) Millions of people around the world unknowingly live with a deadly trio: diabetes, high blood pressure and kidney disease. Often, they only realise the connection when it is ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Semaglutide, a diabetes drug, significantly lowers the risk of heart attacks and strokes in people with type 2 diabetes.

In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...